Translate your next-generation
sequencing data into actionable
information for clinical testing,
disease research, and
Genome interpretation software solutions for clinicians and researchers
Omicia’s Opal™ platform integrates clinically-validated genome analysis algorithms and automated clinical annotations, enabling you to identify and report on disease-causing genes with unprecedented accuracy and efficiency.
Learn how Opal can help you make sense of your genomic data. Schedule a free Opal demonstration.
A primer on genome interpretation:
How Omicia is transforming personalized medicine
Solutions for Basic & Translational Research
Causative Disease Gene Identification
Disease Studies with Cohort & Family Data
Shared Gene Variant and Mutation Discovery
Opal Research integrates a suite of disease gene prioritization algorithms and annotation tools to help researchers identify the genetic cause of disease.
Opal’s VAAST and Phevor algorithms are the most effective tools on the market for pinpointing gene variants and de novo mutations in NGS genomic data. Opal provides pre-configured workflows to expedite the interpretation of single genomes, families or cohorts.
Solutions for Clinical Testing
NGS Panel Curation and Interpretation
NGS Reporting on Individuals and Trios
Genome Interpretation for Complex Cases
Opal Clinical is the end-to-end interpretation and reporting software solution for running NGS clinical tests on targeted panels, whole genomes, and exomes.
Our CLIA and HIPAA-compliant platform seamlessly integrates into laboratory information systems, with customizable reports for review, approval, and output to EMRs. Opal’s robust functionality also allows you to assess candidate disease genes to build customized NGS panels.
Opal Clinical Trials
Solutions for Drug Development
Clinical Trials Stratification
Disease-Associated Biomarker Discovery
Cohort Analysis for Shared Mutations
Opal Clinical Trials complements every stage of the clinical trial process, from pre-phase 1 biomarker discovery to later stage analysis of drug response in patient cohorts.
Opal helps to rank and prioritize gene variants of interest, integrating annotations on actionable gene-drug associations to augment study designs. With Opal, you can segment clinical trial participants, and develop therapies as well as companion diagnostics based on genomic signatures.
Omicia’s bioinformatics approach enables the application of genomics to the clinic.
The Opal platform reduces costs, improves the accuracy of interpretation, and increases the speed of reporting.
Pioneers in genomics, diagnostics, and bioinformatics
Omicia’s leaders have proven track records, including senior roles on the Human Genome Project, at LabCorp, Merck, and Quest Diagnostics.
We’ve built the Opal platform to deliver genomics-based solutions that expedite diagnoses, improve medical outcomes, and accelerate understanding of the genetic basis of disease. Meet our leaders >
Trusted by leaders in translational and clinical omics
Over 400 research, pharma, and clinical diagnostics labs rely on Omicia’s technological precision and clinical expertise.
Omicia’s algorithms have been developed in the lab, designed for the clinic, and have been validated in dozens of published research and clinical studies. Read our publications >